Bliss GVS Pharma Share Price
640.55+0.00 (-3.73%)
+300.87% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
BLISSGVS-BENSE
Bliss GVS Pharma Share Price
640.55+0.00 (-3.73%)
+300.87% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 5% | 10% | 7% | 14% |
| 5% | 14% | 22% | 49% |
| 18% | 45% | 67% | 301% |
| 13% | 8% | 10% | 12% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
BLISSGVS-BE
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,908.7 | ₹456593 Cr | 41.64 | 8.29 | 58.23 | ₹11479 Cr |
| 11,120.5 | ₹296741 Cr | 88.24 | 42.53 | 146.01 | ₹2568 Cr |
| 4,626.2 | ₹175578 Cr | 82.66 | 14.04 | 106.21 | ₹2163 Cr |
| 2,304.4 | ₹124380 Cr | 92.83 | 8.17 | 33.94 | ₹889 Cr |
| 1,235 | ₹119700 Cr | 28.64 | 9.27 | 62.23 | ₹5040 Cr |
| 1,396.5 | ₹116771 Cr | 41.71 | 11.08 | 59.16 | ₹4196 Cr |
| 1,421.8 | ₹114397 Cr | 39.49 | 10.86 | 52.6 | ₹3879 Cr |
| 2,636.7 | ₹108641 Cr | 48.44 | 17.23 | 76.25 | ₹1913 Cr |
| 1,803.3 | ₹103971 Cr | 26.06 | 19.57 | 103.44 | ₹3505 Cr |
| 2,002.6 | ₹91413 Cr | 17.56 | 25.26 | 150.99 | ₹5333 Cr |
| 664 | ₹7073 Cr | 43.88 | 4.91 | 18.67 | ₹129 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | Sep 2016 | Jun 2016 | Mar 2016 | Dec 2015 | Sep 2015 | Jun 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹313 Cr | ₹286 Cr | ₹257 Cr | ₹218 Cr | ₹244 Cr | ₹207 Cr | ₹198 Cr | ₹210 Cr | ₹218 Cr | ₹184 Cr | ₹198 Cr | ₹201 Cr | ₹212 Cr | ₹160 Cr | ₹185 Cr | ₹206 Cr | ₹172 Cr | ₹189 Cr | ₹167 Cr | ₹216 Cr | ₹196 Cr | ₹168 Cr | ₹132 Cr | ₹164 Cr | ₹130 Cr | ₹130 Cr | ₹120 Cr | ₹148 Cr | ₹210 Cr | ₹212 Cr | ₹244 Cr | ₹220 Cr | ₹228 Cr | ₹205 Cr | ₹167 Cr | ₹196 Cr | ₹227 Cr | ₹226 Cr | ₹258 Cr | ₹234 Cr | ₹169 Cr | ₹141 Cr | ₹144 Cr | ₹132 Cr | ₹176 Cr | ₹95 Cr |
| ₹8 Cr | ₹10 Cr | ₹11 Cr | ₹18 Cr | ₹8 Cr | ₹35 Cr | ₹12 Cr | ₹15 Cr | ₹7 Cr | ₹4 Cr | ₹6 Cr | ₹5 Cr | ₹13 Cr | ₹5 Cr | ₹3 Cr | ₹6 Cr | ₹2 Cr | ₹7 Cr | ₹12 Cr | ₹6 Cr | ₹5 Cr | ₹8 Cr | ₹6 Cr | ₹4 Cr | ₹7 Cr | ₹7 Cr | ₹19 Cr | ₹6 Cr | ₹13 Cr | ₹2 Cr | ₹3 Cr | -₹4 Cr | ₹25 Cr | ₹14 Cr | ₹6 Cr | ₹2 Cr | ₹15 Cr | ₹4 Cr | -₹7 Cr | ₹8 Cr | ₹3 Cr | ₹8 Cr | ₹4 Cr | ₹6 Cr | ₹8 Cr | ₹6 Cr |
| ₹322 Cr | ₹295 Cr | ₹268 Cr | ₹237 Cr | ₹253 Cr | ₹243 Cr | ₹210 Cr | ₹226 Cr | ₹224 Cr | ₹188 Cr | ₹204 Cr | ₹206 Cr | ₹224 Cr | ₹165 Cr | ₹188 Cr | ₹211 Cr | ₹175 Cr | ₹196 Cr | ₹179 Cr | ₹222 Cr | ₹201 Cr | ₹176 Cr | ₹138 Cr | ₹168 Cr | ₹137 Cr | ₹137 Cr | ₹138 Cr | ₹153 Cr | ₹223 Cr | ₹214 Cr | ₹247 Cr | ₹217 Cr | ₹253 Cr | ₹219 Cr | ₹173 Cr | ₹198 Cr | ₹242 Cr | ₹229 Cr | ₹252 Cr | ₹242 Cr | ₹172 Cr | ₹150 Cr | ₹148 Cr | ₹139 Cr | ₹184 Cr | ₹101 Cr |
| ₹243 Cr | ₹219 Cr | ₹221 Cr | ₹192 Cr | ₹209 Cr | ₹174 Cr | ₹185 Cr | ₹188 Cr | ₹185 Cr | ₹156 Cr | ₹177 Cr | ₹164 Cr | ₹164 Cr | ₹141 Cr | ₹183 Cr | ₹163 Cr | ₹152 Cr | ₹154 Cr | ₹151 Cr | ₹187 Cr | ₹171 Cr | ₹138 Cr | ₹119 Cr | ₹130 Cr | ₹114 Cr | ₹114 Cr | ₹107 Cr | ₹118 Cr | ₹188 Cr | ₹165 Cr | ₹215 Cr | ₹179 Cr | ₹189 Cr | ₹167 Cr | ₹134 Cr | ₹154 Cr | ₹184 Cr | ₹167 Cr | ₹183 Cr | ₹200 Cr | ₹131 Cr | ₹105 Cr | ₹97 Cr | ₹106 Cr | ₹138 Cr | ₹63 Cr |
| ₹89 Cr | ₹86 Cr | ₹56 Cr | ₹53 Cr | ₹52 Cr | ₹77 Cr | ₹33 Cr | ₹45 Cr | ₹47 Cr | ₹38 Cr | ₹34 Cr | ₹49 Cr | ₹67 Cr | ₹29 Cr | ₹9 Cr | ₹53 Cr | ₹27 Cr | ₹46 Cr | ₹32 Cr | ₹40 Cr | ₹35 Cr | ₹42 Cr | ₹23 Cr | ₹42 Cr | ₹27 Cr | ₹27 Cr | ₹35 Cr | ₹38 Cr | ₹38 Cr | ₹51 Cr | ₹35 Cr | ₹40 Cr | ₹66 Cr | ₹55 Cr | ₹43 Cr | ₹50 Cr | ₹63 Cr | ₹68 Cr | ₹69 Cr | ₹53 Cr | ₹45 Cr | ₹48 Cr | ₹52 Cr | ₹35 Cr | ₹51 Cr | ₹41 Cr |
| ₹3 Cr | ₹58 L | ₹2 Cr | ₹1 Cr | ₹3 Cr | ₹5 Cr | ₹2 Cr | ₹1 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹5 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹68 L | ₹1 Cr | ₹2 Cr | ₹94 L | ₹2 Cr | ₹2 Cr | ₹5 Cr | ₹1 Cr | ₹1 Cr | ₹89 L | ₹93 L | ₹96 L | ₹1 Cr | ₹1 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹8 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹7 Cr | ₹2 Cr | ₹5 Cr | ₹5 Cr |
| ₹75 Cr | ₹75 Cr | ₹45 Cr | ₹41 Cr | ₹41 Cr | ₹63 Cr | ₹23 Cr | ₹36 Cr | ₹36 Cr | ₹30 Cr | -₹4 Cr | ₹40 Cr | ₹59 Cr | ₹22 Cr | -₹75 L | ₹47 Cr | ₹20 Cr | ₹39 Cr | ₹26 Cr | -₹39 Cr | ₹30 Cr | ₹37 Cr | ₹17 Cr | ₹37 Cr | ₹20 Cr | ₹20 Cr | ₹13 Cr | ₹34 Cr | ₹34 Cr | ₹47 Cr | ₹32 Cr | ₹36 Cr | ₹63 Cr | ₹51 Cr | -₹1 Cr | ₹39 Cr | ₹52 Cr | ₹56 Cr | ₹60 Cr | ₹38 Cr | ₹36 Cr | ₹41 Cr | ₹43 Cr | ₹31 Cr | ₹41 Cr | ₹33 Cr |
| ₹53 Cr | ₹51 Cr | ₹37 Cr | ₹25 Cr | ₹29 Cr | ₹44 Cr | ₹17 Cr | ₹26 Cr | ₹26 Cr | ₹22 Cr | -₹5 Cr | ₹29 Cr | ₹43 Cr | ₹14 Cr | ₹3 Cr | ₹30 Cr | ₹16 Cr | ₹27 Cr | ₹23 Cr | -₹49 Cr | ₹22 Cr | ₹26 Cr | ₹8 Cr | ₹28 Cr | ₹17 Cr | ₹17 Cr | ₹6 Cr | ₹25 Cr | ₹31 Cr | ₹33 Cr | ₹19 Cr | ₹27 Cr | ₹42 Cr | ₹39 Cr | -₹14 Cr | ₹26 Cr | ₹39 Cr | ₹37 Cr | ₹43 Cr | ₹22 Cr | ₹21 Cr | ₹28 Cr | ₹29 Cr | ₹23 Cr | ₹28 Cr | ₹20 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹11 Cr | ₹11 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr |
| ₹12 Cr | ₹6 Cr | ₹8 Cr | ₹9 Cr | ₹10 Cr | ₹10 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹1171 Cr | ₹1034 Cr | ₹949 Cr | ₹865 Cr | ₹798 Cr | ₹788 Cr | ₹725 Cr | ₹636 Cr | ₹526 Cr | ₹476 Cr | ₹402 Cr | ₹327 Cr | ₹277 Cr | ₹248 Cr | ₹200 Cr | ₹156 Cr |
| ₹1171 Cr | ₹1034 Cr | ₹949 Cr | ₹865 Cr | ₹798 Cr | ₹788 Cr | ₹725 Cr | ₹636 Cr | ₹526 Cr | ₹476 Cr | ₹402 Cr | ₹327 Cr | ₹277 Cr | ₹248 Cr | ₹200 Cr | ₹156 Cr |
| ₹1193 Cr | ₹1050 Cr | ₹967 Cr | ₹884 Cr | ₹819 Cr | ₹808 Cr | ₹736 Cr | ₹646 Cr | ₹536 Cr | ₹487 Cr | ₹413 Cr | ₹337 Cr | ₹287 Cr | ₹258 Cr | ₹211 Cr | ₹167 Cr |
| ₹39 Cr | ₹41 Cr | ₹36 Cr | ₹34 Cr | ₹28 Cr | ₹20 Cr | ₹15 Cr | ₹14 Cr | ₹11 Cr | ₹66 Cr | ₹33 Cr | ₹15 Cr | ₹10 Cr | ₹14 Cr | ₹49,000 | ₹0 |
| ₹0 | ₹20 Cr | ₹36 Cr | ₹41 Cr | ₹23 Cr | ₹33 Cr | ₹37 Cr | ₹33 Cr | ₹6 Cr | ₹26 Cr | ₹30 Cr | ₹55 Cr | ₹79 Cr | ₹90 Cr | ₹38 Cr | ₹4 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹9 Cr | ₹2 Cr | ₹9 Cr | ₹1 Cr | ₹0 | ₹0 |
| -₹16 Cr | ₹30 L | ₹4 Cr | -₹3 Cr | ₹1 Cr | ₹8 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹5 Cr | ₹9 Cr | ₹9 Cr | ₹7 Cr | ₹5 Cr | ₹1 Cr | -₹37 L |
| ₹22 Cr | ₹13 Cr | ₹9 Cr | ₹3 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹13 L | ₹0 | ₹40,000 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹74 L | ₹51 L | ₹58 L |
| ₹9 Cr | ₹37 Cr | ₹51 Cr | ₹43 Cr | ₹29 Cr | ₹45 Cr | ₹46 Cr | ₹38 Cr | ₹13 Cr | ₹33 Cr | ₹50 Cr | ₹68 Cr | ₹96 Cr | ₹97 Cr | ₹39 Cr | ₹4 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹104 Cr | ₹71 Cr | ₹61 Cr | ₹86 Cr | ₹93 Cr | ₹74 Cr | ₹90 Cr | ₹79 Cr | ₹58 Cr | ₹98 Cr | ₹108 Cr | ₹80 Cr | ₹82 Cr | ₹118 Cr | ₹40 Cr | ₹31 Cr |
| ₹94 Cr | ₹73 Cr | ₹62 Cr | ₹58 Cr | ₹68 Cr | ₹54 Cr | ₹57 Cr | ₹50 Cr | ₹124 Cr | ₹100 Cr | ₹53 Cr | ₹70 Cr | ₹42 Cr | ₹24 Cr | ₹6 Cr | ₹4 Cr |
| ₹3 Cr | ₹23 Cr | ₹32 Cr | ₹46 Cr | ₹61 Cr | ₹65 Cr | ₹66 Cr | ₹64 Cr | ₹106 Cr | ₹187 Cr | ₹62 Cr | ₹61 Cr | ₹57 Cr | ₹45 Cr | ₹6 Cr | ₹3 Cr |
| ₹35 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹12 Cr | ₹11 Cr | ₹17 Cr | ₹14 Cr | ₹11 Cr | ₹51 Cr | ₹156 Cr | ₹31 Cr | ₹126 Cr | ₹14 Cr | ₹8 Cr | ₹4 Cr |
| ₹236 Cr | ₹172 Cr | ₹157 Cr | ₹193 Cr | ₹233 Cr | ₹204 Cr | ₹231 Cr | ₹207 Cr | ₹299 Cr | ₹437 Cr | ₹379 Cr | ₹243 Cr | ₹308 Cr | ₹202 Cr | ₹60 Cr | ₹43 Cr |
| ₹1476 Cr | ₹1301 Cr | ₹1212 Cr | ₹1154 Cr | ₹1109 Cr | ₹1077 Cr | ₹1027 Cr | ₹905 Cr | ₹860 Cr | ₹1023 Cr | ₹874 Cr | ₹662 Cr | ₹700 Cr | ₹571 Cr | ₹310 Cr | ₹213 Cr |
| ₹11 Cr | ₹5 Cr | ₹57 Cr | ₹12 Cr | ₹23 Cr | ₹30 Cr | ₹14 Cr | ₹2 Cr | ₹4 Cr | ₹44 Cr | ₹30 Cr | ₹40 Cr | ₹48 Cr | ₹44 Cr | ₹51 Cr | ₹12 Cr |
| ₹3 Cr | ₹71 Cr | ₹88 Cr | ₹98 Cr | ₹105 Cr | ₹119 Cr | ₹121 Cr | ₹102 Cr | ₹118 Cr | ₹225 Cr | ₹132 Cr | ₹160 Cr | ₹173 Cr | ₹147 Cr | ₹45 Cr | ₹8 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹607 Cr | ₹531 Cr | ₹468 Cr | ₹459 Cr | ₹343 Cr | ₹285 Cr | ₹276 Cr | ₹170 Cr | ₹157 Cr | ₹327 Cr | ₹301 Cr | ₹294 Cr | ₹262 Cr | ₹206 Cr | ₹64 Cr | ₹41 Cr |
| ₹149 Cr | ₹126 Cr | ₹98 Cr | ₹81 Cr | ₹63 Cr | ₹51 Cr | ₹35 Cr | ₹25 Cr | ₹21 Cr | ₹23 Cr | ₹75 Cr | ₹59 Cr | ₹49 Cr | ₹38 Cr | ₹24 Cr | ₹21 Cr |
| ₹459 Cr | ₹405 Cr | ₹369 Cr | ₹378 Cr | ₹281 Cr | ₹234 Cr | ₹241 Cr | ₹145 Cr | ₹136 Cr | ₹304 Cr | ₹225 Cr | ₹234 Cr | ₹213 Cr | ₹168 Cr | ₹40 Cr | ₹20 Cr |
| ₹6 Cr | ₹21 Cr | ₹8 Cr | ₹3 Cr | ₹22 Cr | ₹2 Cr | ₹0 | ₹47 Cr | ₹47 L | ₹4 Cr | ₹9 Cr | ₹0 | ₹4 Cr | ₹65 L | ₹6 Cr | ₹8 Cr |
| ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹1 L | ₹72 L | ₹72 L | ₹6 Cr | ₹1 Cr | ₹11 L | ₹1 L | ₹1 L | ₹1 L | ₹1,000 | ₹1,000 |
| ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹1 L | ₹72 L | ₹72 L | ₹6 Cr | ₹1 Cr | ₹11 L | ₹1 L | ₹1 L | ₹1 L | ₹1,000 | ₹1,000 |
| ₹30 Cr | ₹20 Cr | ₹15 Cr | ₹18 Cr | ₹24 Cr | ₹13 Cr | ₹15 Cr | ₹19 Cr | ₹27 Cr | ₹11 Cr | ₹57 Cr | ₹10 Cr | ₹12 Cr | ₹51 Cr | ₹53 Cr | ₹29 Cr |
| ₹31 Cr | ₹27 Cr | ₹5 Cr | ₹54 Cr | ₹1 Cr | ₹62 Cr | ₹1 Cr | ₹33 L | ₹29 L | ₹137 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹530 Cr | ₹477 Cr | ₹401 Cr | ₹456 Cr | ₹332 Cr | ₹312 Cr | ₹257 Cr | ₹211 Cr | ₹170 Cr | ₹457 Cr | ₹291 Cr | ₹245 Cr | ₹230 Cr | ₹220 Cr | ₹100 Cr | ₹57 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹1 Cr | ₹0 | ₹56 L | ₹5 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹1,000 | ₹0 | ₹0 | ₹0 | ₹0 | ₹80 L | ₹0 |
| ₹151 Cr | ₹126 Cr | ₹118 Cr | ₹103 Cr | ₹124 Cr | ₹99 Cr | ₹74 Cr | ₹77 Cr | ₹59 Cr | ₹49 Cr | ₹39 Cr | ₹34 Cr | ₹33 Cr | ₹33 Cr | ₹13 Cr | ₹12 Cr |
| ₹517 Cr | ₹439 Cr | ₹404 Cr | ₹385 Cr | ₹393 Cr | ₹464 Cr | ₹548 Cr | ₹461 Cr | ₹298 Cr | ₹254 Cr | ₹301 Cr | ₹247 Cr | ₹215 Cr | ₹245 Cr | ₹129 Cr | ₹120 Cr |
| ₹167 Cr | ₹213 Cr | ₹216 Cr | ₹103 Cr | ₹178 Cr | ₹145 Cr | ₹103 Cr | ₹107 Cr | ₹89 Cr | ₹151 Cr | ₹78 Cr | ₹57 Cr | ₹80 Cr | ₹50 Cr | ₹58 Cr | ₹18 Cr |
| ₹14 Cr | ₹15 Cr | ₹17 Cr | ₹7 Cr | ₹14 Cr | ₹18 Cr | ₹16 Cr | ₹26 Cr | ₹97 Cr | ₹33 Cr | ₹15 Cr | ₹18 Cr | ₹11 Cr | ₹12 Cr | ₹4 Cr | ₹5 Cr |
| ₹96 Cr | ₹24 Cr | ₹55 Cr | ₹95 Cr | ₹69 Cr | ₹40 Cr | ₹28 Cr | ₹23 Cr | ₹146 Cr | ₹78 Cr | ₹150 Cr | ₹61 Cr | ₹130 Cr | ₹9 Cr | ₹5 Cr | ₹3 Cr |
| ₹946 Cr | ₹817 Cr | ₹811 Cr | ₹697 Cr | ₹777 Cr | ₹765 Cr | ₹770 Cr | ₹693 Cr | ₹690 Cr | ₹566 Cr | ₹583 Cr | ₹417 Cr | ₹469 Cr | ₹349 Cr | ₹210 Cr | ₹157 Cr |
| ₹711 Cr | ₹644 Cr | ₹653 Cr | ₹504 Cr | ₹544 Cr | ₹562 Cr | ₹539 Cr | ₹486 Cr | ₹390 Cr | ₹129 Cr | ₹204 Cr | ₹174 Cr | ₹162 Cr | ₹147 Cr | ₹150 Cr | ₹114 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹43 L | ₹1 Cr | ₹2 Cr | ₹0 | ₹0 |
| ₹1476 Cr | ₹1301 Cr | ₹1212 Cr | ₹1154 Cr | ₹1109 Cr | ₹1077 Cr | ₹1027 Cr | ₹905 Cr | ₹860 Cr | ₹1023 Cr | ₹874 Cr | ₹662 Cr | ₹700 Cr | ₹571 Cr | ₹310 Cr | ₹213 Cr |
| ₹112 | ₹99 | ₹92 | ₹84 | ₹78 | ₹77 | ₹71 | ₹63 | ₹52 | ₹47 | ₹40 | ₹33 | ₹28 | ₹25 | ₹20 | ₹16 |
| ₹112 | ₹99 | ₹92 | ₹84 | ₹78 | ₹77 | ₹71 | ₹63 | ₹52 | ₹47 | ₹40 | ₹33 | ₹28 | ₹25 | ₹20 | ₹16 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹190 Cr | ₹126 Cr | ₹146 Cr | ₹106 Cr | ₹128 Cr | ₹104 Cr | ₹129 Cr | ₹182 Cr | ₹179 Cr | ₹175 Cr | ₹148 Cr | ₹96 Cr | ₹71 Cr | ₹109 Cr | ₹79 Cr | ₹0 |
| ₹96 Cr | ₹71 Cr | ₹38 Cr | ₹58 Cr | -₹32 Cr | ₹46 Cr | ₹27 Cr | -₹11 Cr | ₹18 Cr | ₹36 Cr | ₹18 Cr | ₹17 Cr | ₹24 Cr | ₹10 Cr | ₹5 Cr | ₹0 |
| -₹104 Cr | -₹51 Cr | -₹47 Cr | -₹85 Cr | ₹73 Cr | -₹58 Cr | -₹70 Cr | -₹183 Cr | -₹141 Cr | ₹113 Cr | -₹8 Cr | -₹67 Cr | -₹19 Cr | -₹74 Cr | -₹38 Cr | ₹0 |
| ₹181 Cr | ₹145 Cr | ₹138 Cr | ₹79 Cr | ₹169 Cr | ₹93 Cr | ₹85 Cr | -₹12 Cr | ₹56 Cr | ₹325 Cr | ₹158 Cr | ₹46 Cr | ₹75 Cr | ₹45 Cr | ₹46 Cr | ₹0 |
| ₹139 Cr | ₹106 Cr | ₹103 Cr | ₹34 Cr | ₹135 Cr | ₹64 Cr | ₹47 Cr | ₹40 Cr | ₹18 Cr | ₹289 Cr | ₹113 Cr | ₹38 Cr | ₹41 Cr | ₹7 Cr | ₹35 Cr | ₹0 |
| -₹38 Cr | -₹76 Cr | -₹83 Cr | -₹8 Cr | -₹93 Cr | -₹47 Cr | -₹48 Cr | -₹74 Cr | ₹50 Cr | -₹231 Cr | -₹50 Cr | -₹29 Cr | -₹11 Cr | -₹124 Cr | -₹22 Cr | ₹0 |
| -₹89 Cr | -₹30 Cr | -₹21 Cr | -₹25 Cr | -₹24 Cr | -₹21 Cr | -₹6 Cr | ₹17 Cr | -₹76 Cr | -₹10 Cr | -₹40 Cr | -₹42 Cr | -₹8 Cr | ₹110 Cr | ₹26 Cr | ₹0 |
| ₹11 Cr | ₹13 L | -₹1 Cr | ₹2 Cr | ₹19 Cr | -₹4 Cr | -₹7 Cr | -₹17 Cr | -₹8 Cr | ₹48 Cr | ₹23 Cr | -₹33 Cr | ₹22 Cr | -₹8 Cr | ₹40 Cr | ₹0 |
| ₹24 Cr | ₹24 Cr | ₹25 Cr | ₹22 Cr | ₹13 Cr | ₹15 Cr | ₹15 Cr | ₹37 Cr | ₹47 Cr | ₹0 | ₹5 Cr | ₹39 Cr | ₹28 Cr | ₹58 Cr | ₹18 Cr | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹5 L | ₹0 | ₹0 | ₹17 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹10 L | ₹10 L | -₹15 L | ₹1 Cr | -₹10 Cr | ₹2 Cr | ₹8 Cr | -₹5 Cr | -₹2 Cr | -₹18 Cr | -₹34 L | -₹53 L | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹35 Cr | ₹24 Cr | ₹24 Cr | ₹25 Cr | ₹22 Cr | ₹13 Cr | ₹15 Cr | ₹15 Cr | ₹37 Cr | ₹47 Cr | ₹28 Cr | ₹5 Cr | ₹50 Cr | ₹50 Cr | ₹58 Cr | ₹0 |
Fundamental Ratios
Consolidated
Standalone

No results found
Bliss GVS Pharma Share Price
640.55+0.00 (-3.73%)
+300.87% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 3 out of 9 oscillators
RSI
47.87Neutral
STOCH %K
49.09Neutral
MACD Level(12,26)
2.77Buy
Ultimate Oscillator
47.08Sell
Aroon Oscillator
-56.00Sell
BOP
-0.46Sell
CCI
29.03Neutral
Williams %R
-50.91Neutral
Momentum
23.35Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 6 out of 9 moving averages
EMA 9
654.66Sell
SMA 9
658.68Sell
EMA 21
650.79Sell
SMA 21
644.12Sell
EMA 50
638.87Buy
SMA 50
663.77Sell
EMA 200
481.87Buy
SMA 200
442.54Buy
WMA 20
649.84Sell
Pivot
Pivot
Classic
Resistance 5
753.52
Resistance 4
733.12
Resistance 3
712.72
Resistance 2
692.32
Resistance 1
678.83
Pivot
671.92
Support 1
658.43
Support 2
651.52
Support 3
631.12
Support 4
610.72
Support 5
590.32
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Bliss GVS Pharma Share Price
640.55+0.00 (-3.73%)
+300.87% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 50.07% | 35.01% | 35.36% | 35.36% | 35.39% | 35.44% |
| 5.03% | 8.07% | 10.45% | 14.54% | 13.27% | 12.65% |
| 9.47% | 9.06% | 5.04% | 5.78% | 5.98% | 6.54% |
| 0.00% | 0.26% | 0.00% | 0.00% | 0.00% | 0.00% |
| 35.43% | 47.60% | 49.15% | 44.32% | 45.36% | 45.37% |
Bulk & block deals
Name
Anupam Rasayan India Limited
Arian Investment Ltd
Nova Vida Limited
Arian Investment Ltd
Nova Vida Limited
Arian Investment Ltd
Mateus Ltd
Mateus Ltd
Arian Investment Ltd
Hrti Private Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 28 Sep 2026 | Purchase | 162.74 Cr | ₹723.29 | 22.50 L | Bulk | 2.116044 | NSE |
| 21 Jul 2026 | Sell | 33.95 Cr | ₹485 | 7 L | Bulk | 0.658861 | NSE |
| 21 Jul 2026 | Purchase | 33.95 Cr | ₹485 | 7 L | Block | 0.658861 | NSE |
| 21 Jul 2026 | Sell | 33.95 Cr | ₹485 | 7 L | Block | 0.658861 | NSE |
| 21 Jul 2026 | Purchase | 33.95 Cr | ₹485 | 7 L | Bulk | 0.658861 | NSE |
| 29 Jun 2026 | Sell | 56.35 Cr | ₹490 | 11.50 L | Block | 1.084331 | NSE |
| 29 Jun 2026 | Purchase | 56.35 Cr | ₹490 | 11.50 L | Block | 1.084331 | NSE |
| 29 Jun 2026 | Purchase | 56.35 Cr | ₹490 | 11.50 L | Bulk | 1.084331 | NSE |
| 29 Jun 2026 | Sell | 56.35 Cr | ₹490 | 11.50 L | Bulk | 1.084331 | NSE |
| 29 May 2026 | Purchase | 19.20 Cr | ₹419.26 | 4.58 L | Bulk | 0.432935 | NSE |
Insider trading & SAST
Client name
Mates Visa Consultancy Private Limited
Gulbarga Trading And Investment Private Limited
Narsimha Shibroor Kamath
Mates Visa Consultancy Private Limited
Life Insurance Corporation Of India
Clarus Capital I & Others
Gagan Harsh Sharma & Pacs
Punita Sharma & Pacs
Mr. Gagan Harsh Sharma
Mrs. Punita Sharma
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 06 Oct 2026 | Promoter | — | 47.949173 | 47.95 | 3,487.35 Cr | ₹684 | 5.10 Cr | 30 Sep 2026 | Pledge Creation | 5,09,84,595 | Insider Trading | — | Equity |
| 30 Sep 2026 | Other | Disposal | 5.49 | 0 | 0 | — | 58.32 L | 29 Sep 2026 | Sale of Shares - offmarket | 0 | SAST | 29(2) | Equity Shares |
| 30 Sep 2026 | Promoter | Disposal | 30.52 | 0 | 0 | — | 3.24 Cr | 29 Sep 2026 | Sale of Shares - offmarket | 0 | SAST | 29(2) | Equity Shares |
| 30 Sep 2026 | Other | Acquisition | 30.52 | 30.52 | 0 | — | 3.24 Cr | 29 Sep 2026 | Acquisition of shares - offmarket | 3,24,37,224 | SAST | 29(1) | Equity Shares |
| 24 Aug 2026 | Other | Disposal | 2.15 | 2.95 | 0 | — | 21.32 L | 09 Sep 2020 - 10 Aug 2026 | Market | 31,44,284 | SAST | 29(2) | — |
| 31 Jul 2026 | Other | Acquisition | 0.17 | 5.13 | 0 | — | 1.85 L | 20 Jul 2026 | Market | 54,38,523 | SAST | 29(1) | — |
| 17 Jun 2026 | Promoter | Disposal | 0.21 | — | 0 | — | 2.17 L | 18 May 2026 | Market | — | SAST | 29(2) | — |
| 27 May 2026 | Promoter | Disposal | 0.02 | — | 0 | — | 24.96 K | 18 May 2026 | Market | — | SAST | 29(2) | — |
| 21 May 2026 | Promoter | Disposal | 0.205242 | 0 | 6.20 Cr | ₹285.78 | 2.17 L | 18 May 2026 | Market Sale | 0 | Insider Trading | — | Equity Shares |
| 21 May 2026 | Promoter Group | Disposal | 0.023596 | 0 | 71.14 L | ₹285 | 24.96 K | 18 May 2026 | Market Sale | 0 | Insider Trading | — | Equity Shares |
Bliss GVS Pharma Share Price
640.55+0.00 (-3.73%)
+300.87% past 1 Year
Bliss GVS Pharma Limited is a fast-growing Pharmaceutical Company with a proven track record of developing manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market.
Corporate Actions
Date
Type
Details
Company details
Bliss GVS Pharma Share Price
640.55+0.00 (-3.73%)
+300.87% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Bliss GVS Pharma Share Price
640.55+0.00 (-3.73%)
+300.87% past 1 Year
News
1 of 20
ResultBLISSGVS29 Oct 2026
Bliss GVS reported second-quarter EBITDA of Rs 80.60 crores, up from Rs 30.80 crores a year earlier, representing approximately 161.7 percent YoY growth. EBITDA margin improved to 25.71 percent from 12.58 percent in the corresponding quarter, an expansion of 13.13 percentage points. Revenue and PAT figures, QoQ comparisons, consensus estimates, management commentary, and market reaction were not provided. The result indicates significant year-on-year operating profitability improvement for the pharmaceutical formulations company.
Bliss GVS Pharma Reports Strong Second Quarter Profit Growth
ResultBLISSGVS29 Oct 2026
Bliss GVS Pharma reported consolidated Q2 net profit of Rs 52.25 crores, compared with Rs 27.30 crores in the corresponding quarter of the previous year, representing year-on-year growth of approximately 91.4%. Revenue, EBITDA, operating margin, net margin, quarter-on-quarter performance, and street expectations were not provided in the available update and are therefore not included.
The substantial increase in consolidated profit indicates improved quarterly earnings performance for the pharmaceutical company. No management commentary, forward guidance, or market reaction was provided. The result is classified as a routine company-specific earnings development with a positive effect on the stock outlook.
Bliss GVS Pharma Reports Strong Second Quarter Revenue Growth
ResultBLISSGVS29 Oct 2026
Bliss GVS Pharma reported second-quarter revenue of Rs 313.00 crores, up from Rs 240.00 crores in the corresponding quarter of the previous year, representing year-on-year growth of approximately 30.42%. The available information does not provide EBITDA, PAT, operating margin, net margin, sequential revenue comparison, analyst consensus, or management guidance. No market reaction has been specified.
Bliss GVS Pharma Reports Rs 136.70 Crores NSE Block Trade
Block DealBLISSGVS28 Sept 2026
Bliss GVS Pharma recorded an NSE block trade involving approximately 1,859,916 shares at Rs 735.00 per share, representing a total transaction value of about Rs 136.70 crores. The available information does not disclose the identities of the buyer or seller, the percentage stake transferred, or whether the transaction involved promoters, institutions, strategic investors, or funds.
The reported block-trade price was above the recent market price of approximately Rs 709.00, implying a premium of about 3.7 percent. No verified information is available on subsequent share-price movement attributable to the transaction.
Bliss GVS Pharma informs about open offer
Stock NewsBLISSGVS9 Jun 2026
NULL
Bliss GVS Pharma rises on securing Inspection Closure Report from WHO
Stock NewsBLISSGVS3 Jun 2026
The company’s Palghar facility has been confirmed to be in compliance with the GMP standards published by WHO
Bliss GVS Pharma gains WHO GMP compliance approval for Palghar facility
Stock NewsBLISSGVS2 Jun 2026
Bliss GVS Pharma has received World Health Organization Good Manufacturing Practice (WHO GMP) compliance approval for its manufacturing facility located at Palghar. WHO GMP approval is a key global quality benchmark that certifies a plant’s adherence to stringent standards in areas such as production processes, quality control, documentation, and facility management. This regulatory milestone enhances the company’s manufacturing credibility for regulated and semi-regulated markets, particularly for supplying medicines to international health agencies and government procurement programmes. The approval can support the company’s strategy to expand exports, participate in larger international tenders, and deepen its presence in global markets where WHO-prequalified or WHO GMP-compliant facilities are preferred. Over time, this can help improve capacity utilisation at the Palghar plant and support better operating leverage.
From an earnings perspective, WHO GMP compliance for the Palghar plant increases Bliss GVS Pharma’s ability to scale volumes of existing products and launch additional formulations targeted at overseas markets, potentially improving revenue visibility and margin profile as higher-value export opportunities open up. The approval may also strengthen the company’s competitive positioning relative to peers lacking comparable global certifications, thereby aiding medium-term market share gains in selected therapeutic and geographic segments. While the immediate financial impact will depend on the pace of order inflows and regulatory registrations in target countries, the development is structurally positive for the company’s growth and reputation in the global pharmaceutical supply chain. Investors and market participants are likely to track subsequent disclosures on new contracts, capacity ramp-up, and product pipeline additions linked to the Palghar facility.
Bliss GVS Pharma informs about disclosure
Stock NewsBLISSGVS21 May 2026
NULL
Bliss GVS Pharma Q4 Consolidated Net Profit Rises to Rs 35.50 Crores, Up from Rs 15.50 Crores YoY
ResultBLISSGVS13 May 2026
Bliss GVS Pharma reported its Q4 consolidated net profit at Rs 35.50 crores, marking a significant year-on-year increase from Rs 15.50 crores in the previous year's corresponding quarter. This robust growth in profitability underscores a strong performance for the quarter.
The earnings announcement highlights the company's ability to enhance bottom-line results, though specific details on revenue, EBITDA, or margin expansions were not disclosed in the available context. No comparisons to street expectations or consensus estimates were provided. Management commentary or forward guidance remains unavailable in the report.
This result reflects positively on the pharmaceutical sector player's operational execution amid market conditions.
Bliss GVS Pharma Reports Q4 Revenue Growth to Rs 257 Crores, Up from Rs 198 Crores YoY
ResultBLISSGVS13 May 2026
Bliss GVS Pharma announced its Q4 financial results, recording revenue of Rs 257.00 crores, marking a significant year-over-year (YoY) increase from Rs 198.00 crores. This growth reflects improved performance in the quarter, though additional details such as EBITDA, PAT, or margin trends were not specified in the update. The results highlight the company's revenue expansion amid its operations in the pharmaceutical sector.
No information on quarter-over-quarter (QoQ) comparisons, consensus estimates, or management guidance was provided. Market reaction or stock movement post-results is not detailed in the available context. Investors may monitor upcoming disclosures for comprehensive earnings metrics including profitability and outlook.
Bliss GVS Pharma Reports Strong Q4 EBITDA Growth to Rs 44.40 Crores, Margin Expands to 17.3%
ResultBLISSGVS13 May 2026
Bliss GVS Pharma announced robust Q4 financial results, with EBITDA surging to Rs 44.40 crores from Rs 21.10 crores in the year-ago quarter, reflecting a year-over-year (YoY) increase of over 110%. The EBITDA margin significantly improved to 17.3% compared to 10.65% in Q4 FY25, indicating enhanced operational efficiency and profitability.
This strong performance underscores the company's ability to drive earnings growth amid market conditions. No details on revenue, PAT, or QoQ comparisons were provided in the update. The results highlight positive momentum in the pharmaceutical sector for Bliss GVS Pharma, listed under symbol BLISSGVS on NSE/BSE.
Bliss GVS Pharma reports Profit after tax of 32.42 Crores, in the March 2026 quarter
ResultBLISSGVS12 May 2026
NULL
Bliss GVS Pharma informs about credit rating
Stock NewsBLISSGVS8 Apr 2026
NULL
Bliss GVS Pharma informs about trading window closure
Stock NewsBLISSGVS31 Mar 2026
NULL
Bliss GVS Pharma Addresses Rumors of Acquiring Anupam Rasayan, No Official Decision Yet.
Stock NewsBLISSGVS13 Feb 2026
Bliss GVS Pharma has issued a statement addressing market rumors regarding a potential acquisition of Anupam Rasayan. The company clarified that no official decision has been made on the matter.
This development pertains to speculation in the equity markets under banking and corporate news categories. Bliss GVS Pharma, listed with symbol BLISSGVS on NSE/BSE, directly refuted the rumors, emphasizing the absence of any finalized corporate action such as M&A.
No specific details on quantum, stake size, or financial impact were provided in the clarification. The statement aims to curb misinformation and maintain market transparency amid ongoing stock alerts and movers.
Anupam Rasayan May Acquire Stake in Bliss GVS Pharma as per CNBC Aawaz Report.
Stock NewsBLISSGVS13 Feb 2026
CNBC Aawaz reports that Anupam Rasayan may acquire a stake in Bliss GVS Pharma. The news falls under equity category with subcategories including BANKING, CORPORATE NEWS, MOVERS TODAY, STOCK ALERTS. The symbol associated is BLISSGVS, indicating potential corporate action in the pharmaceutical sector.
This development points to a possible M&A activity where Anupam Rasayan, known for its recent acquisitions in specialty chemicals, could take a stake in Bliss GVS Pharma. Such a move may impact Bliss GVS Pharma's market position, earnings potential, or leverage, depending on the stake size and terms. No specific quantum like percentage stake, valuation in Rs crores, or deal structure is detailed in the report. Stock price impact on the day is not mentioned.
Bliss GVS Pharma - Quaterly Results
ResultBLISSGVS10 Feb 2026
NULL
Bliss GVS Pharma Reports Strong Q3 EBITDA Growth of 16% YoY to Rs 34.80 Crores.
ResultBLISSGVS10 Feb 2026
Bliss GVS Pharma announced Q3 results showing EBITDA of Rs 34.80 crores, up from Rs 29.90 crores YoY, with EBITDA margin expanding to 15.94% from 14.2% YoY. Detailed financials from quarterly results indicate revenue at Rs 207.47 crores, reflecting 4.79% QoQ growth from Rs 197.99 crores and 12.98% YoY growth. Operating profit stood at Rs 40.92 crores, marking a significant 197.60% QoQ increase from Rs 13.75 crores and 624.25% YoY growth. Profit Before Tax reached Rs 63.10 crores, up 169.20% QoQ and 109.84% YoY. Net profit was Rs 43.04 crores, with 176.96% QoQ growth and 107.92% YoY increase.
These figures highlight robust profitability improvement, though specific street expectations are not provided in the data. No management commentary or forward guidance is mentioned. Recent stock performance shows mixed trends, with 1-day change at -1.19% and 1-year gain of 23.81%.
Bliss GVS Pharma Reports Q3 Revenue Growth to Rs 220 Crores, Up from Rs 210 Crores YoY.
ResultBLISSGVS10 Feb 2026
Bliss GVS Pharma Ltd announced its Q3 results with revenue at Rs 220.00 crores, marking a year-over-year increase from Rs 210.00 crores. This represents approximately 4.76% YoY growth based on the provided figures[1].
Supporting data from recent quarterly performance indicates revenue for Sep '25 at Rs 264.58 crores, up 8.92% QoQ from Rs 242.92 crores in Jun '25. However, EBITDA declined to Rs 51.94 crores from Rs 76.78 crores QoQ, a drop of 32.35%, and net profit fell to Rs 28.59 crores from Rs 44.36 crores, down 35.55% QoQ[1]. Alternative sources report revenue at Rs 207.47 crores with strong YoY growth of 12.98% and QoQ of 4.79%, alongside net profit of Rs 43.04 crores, up 107.92% YoY[2].
Stock price showed volatility in early February 2026, rising from Rs 171.85 on Feb 1 to Rs 203.75 on Feb 9, amid anticipation of Q3 results scheduled for Feb 10, 2026[1]. No specific consensus expectations, margin trends, or management guidance are detailed in the context.
Bliss GVS Pharma Q3 FY26 Net Profit Declines YoY to Rs 23.30 Crores
ResultBLISSGVS10 Feb 2026
Bliss GVS Pharma Ltd reported Q3 FY26 consolidated net profit of Rs 23.30 crores, representing a marginal YoY decline from Rs 23.80 crores in Q3 FY25. Revenue for the quarter stood at Rs 264.58 crores, reflecting QoQ growth of 8.92% from Rs 242.92 crores in Q2 FY26, though this growth was offset by operational headwinds. EBITDA declined significantly by 32.35% QoQ to Rs 51.94 crores from Rs 76.78 crores, while net profit contracted 35.55% sequentially, indicating margin compression despite top-line recovery. The company's operating performance reflects mixed momentum with revenue expansion challenged by cost pressures and lower profitability conversion. Stock price as of February 5, 2026 closed at Rs 185.50, within a recent range of Rs 171.85 to Rs 203.75 (February 1-9, 2026). The quarter represents a stabilization phase following September 2024's 42.66% YoY profit decline, though sequential improvement in revenue suggests underlying demand resilience in the pharmaceutical segment.

